AdjuTec Pharma’s novel resistance breaker APC148, that recently completed a phase 1 safety study, will be tested in combination with different antibiotics. The company’s lead product APC301 has shown excellent in vitro and in vivo efficacy towards several multidrug resistant bacteria and showed most recently superiority to all competitor products in a global collection of 176 pathogens (Enterobacterales), describes the company.

“The signing of the Eurostars consortium agreement is exciting news for AdjuTec Pharma as it will expand our technology into a new patient population with severe lung infection. Together with our partners we will investigate new drug combinations and formulations to broaden the commercial potential of partner technologies and competences,” says AdjuTec Pharma’s COO and project coordinator, Bjørn Klem .

Partners: Vivexa, PureIMS, and CTC

The consortium will perform in vitro microbiology screening and toxicology testing. Partners are Vivexia (France), a laboratory who will perform in vivo microbiology testing, PureIMS (The Netherlands), based on its proprietary inhaler, will develop and investigate inhalation characteristics of the formulation, and CTC (Sweden), a clinical CRO who will test lung availability of test compounds in healthy volunteers.

The consortium will investigate the most efficient drug combination of selected multidrug resistant bacterial strains and secure adequate drug dosing to the lungs.

The Eurostars project will run for three years and starts end 2025.